
Causes of pre-treatment loss to follow-up in patients with TB
OBJECTIVE: To determine the proportion of bacteriologically confirmed pre-treatment lost to follow-up (LTFU) patients with TB found at the study settings in 2020.
DESIGN: This was a retrospective cohort study in which the TB laboratory and treatment registers at the study sites were cross-matched.
RESULTS: A total of 1,085 bacteriologically confirmed patients with TB were found in the laboratory TB registers at the study settings. Of these, 809 (74.6%) were males, whereas 8 (0.7%) were children, 1,005 (92.6%) were diagnosed using Xpert, 78 (7.2%) by microscopy. A total of 91 (8.4%, 95% CI 6.8–10.2) were determined to be pre-treatment LTFU. Those who had very low (14.0%, 95% CI 8.5–21.2) and low (11.8%, 95% CI 8.4–16.0) results on Xpert were respectively 3.1 (95% CI 1.6–6.0) and 2.6 (95% CI 1.4–4.8) times more likely to become pre-treatment LTFU than those who had medium (4.5%, 95% CI 2.5–7.4) results. The proportions of pre-treatment LTFU varied among the study sites from 0.7% to 16.1%.
CONCLUSION: Health facilities should strive to account for every patient with TB, with particular attention to those who are bacteriologically confirmed.
Keywords: bacteriologically confirmed; cross-match; treatment
Document Type: Research Article
Affiliations: 1: Japan Anti-Tuberculosis Association, Lusaka, Zambia 2: Research Institute of Tuberculosis, Tokyo, Japan 3: Ministry of Health, Lusaka District Health Office, Lusaka, Zambia
Publication date: December 21, 2022
Public Health Action (PHA), The Union's quarterly Open Access journal, welcomes the submission of articles on operational research. It publishes high-quality scientific research on health services, providing new knowledge on how to improve access, equity, quality and efficiency of health systems and services.
The Editors will consider any manuscript reporting original research on quality improvements, cost-benefit analysis, legislation, training and capacity building, with a focus on all relevant areas of public health (e.g. infection control, nutrition, TB, HIV, vaccines, smoking, COVID-19, microbial resistance, outbreaks etc).
- Editorial Board
- Information for Authors
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content